<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01062269</url>
  </required_header>
  <id_info>
    <org_study_id>OO1</org_study_id>
    <nct_id>NCT01062269</nct_id>
  </id_info>
  <brief_title>A Single Research Site Bile Acid Sequestrant Acceptability (BASA) Scale Pilot Validation Study</brief_title>
  <official_title>A Randomized Single Blind Placebo Controlled Single Research Site Bile Acid Sequestrant Acceptability (BASA) Scale Pilot Validation Study in Generally Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Louisville Metabolic and Atherosclerosis Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Provident Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Louisville Metabolic and Atherosclerosis Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the research study is (1) to rate the taste, texture, appearance, and
      mixability of 2 different doses of orange flavored cholestyramine compared to orange flavored
      Tang, (2) rank the importance of the taste, texture, appearance, and mixability when rating
      cholestyramine and Tang to determine the accuracy and usefulness of a taste test
      questionnaire.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate patient acceptability of 2 doses of
      orange-flavored generic Questran (cholestyramine) versus orange-flavored Tang Drink Mix (a
      commercial powdered orange drink without cholestyramine) via 2 BASA scales. A second
      objective is to assess the 2 different versions of the BASA scale. One version will be
      unweighted with the score based upon the aggregate score of each acceptability component. A
      second version will be weighted based upon subjectively-reported importance of the
      acceptability components. The one main study objective or focus is to determine which version
      of a BASA scale best differentiates patient acceptability of a bile acid sequestrant
      (cholestyramine) versus a placebo control powder (containing no bile acid sequestrant)
      thereby determining which BASA scale is the best validated instrument for future studies in
      assessing and comparing patient acceptability of bile acid sequestrants.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Acceptability of Orange-flavored Generic Questran (Cholestyramine) vs. Tang (a Commercial Powdered Orange Drink) Via 2 Versions of a Bile Acid Sequestrant Acceptability (BASA) Scale.</measure>
    <time_frame>1 Day</time_frame>
    <description>The Bile Acid Sequestrant Acceptability Scale has 4 scoring categories: taste, texture, appearance and mixability. Participants rank each category separately. The best possible score for each category is 5 and the worst possible score is 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weighted vs. Unweighted BASA Scale</measure>
    <time_frame>1 Day</time_frame>
    <description>The total aggregate scores for the complete BASA scale were calculated for Cholestyramine 4g, Cholestyramine 12g, and Tang. The total best possible score was 20 and the total worst possible score was 4. A weighted aggregate BASA scale score was also calculated for the Cholestyramine 4g, Cholestyramine 12g, and Tang. The best possible weighted score was 60 and the worst possible weighted score was 4.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cholestyramine 4 grams</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cholestyramine 12 grams</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tang</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholestyramine</intervention_name>
    <description>Cholestyramine 4 grams one time dose</description>
    <arm_group_label>Cholestyramine 4 grams</arm_group_label>
    <other_name>Questran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholestyramine</intervention_name>
    <description>Cholestyramine 12 grams one dose, one day</description>
    <arm_group_label>Cholestyramine 12 grams</arm_group_label>
    <other_name>Questran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tang</intervention_name>
    <description>Tang one dose one day</description>
    <arm_group_label>Tang</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects or generally healthy volunteers are eligible for inclusion if they meet the
        following inclusion criteria during the Screening Period:

          -  Men or women 18-70 years of age

          -  In general good health.

          -  Subjects are capable of giving informed consent, or if appropriate, have an acceptable
             surrogate capable of giving consent on the subject's behalf.

          -  Subjects are willing and readily able to be contacted for post-study safety phone call
             assessments one to seven days after the single study visit.

        Exclusion Criteria:

          -  Prior intolerance to bile acid sequestrants

          -  Women who are either pregnant, or who are not practicing any form of birth control.

          -  Prior gastrointestinal surgery

          -  History of ongoing gastrointestinal symptoms (indigestion, constipation, or diarrhea)

          -  History of bowel obstruction, malabsorption, or irritable bowel syndrome

          -  History of esophageal disease

          -  Current or past history of gall bladder disease

          -  Subjects enrolled in another experimental (interventional) protocol within the past 30
             days prior to visit 1.

          -  Diagnosis of diabetes mellitus

          -  Known history of triglyceride levels &gt; 300 mg/dl.

          -  History of alcohol or drug abuse within 1 year of study entry

          -  Alcohol intake that exceeds more than 2 units of alcohol drinks per day

          -  Blood donation within 8 weeks of the study or anticipation of blood donation during
             the study.

          -  Exposure to bile acid sequestrants (colesevelam HCl, cholestyramine, colestipol within
             30 of visit 1).

          -  Any other situation in which the Investigator makes the judgment that participation in
             the study would not be in the best interest of the study participant, or in the best
             interest of providing reliable study data.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harold E Bays, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>L-MARC Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>L-MARC Research Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2010</study_first_submitted>
  <study_first_submitted_qc>February 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2010</study_first_posted>
  <results_first_submitted>May 18, 2010</results_first_submitted>
  <results_first_submitted_qc>July 14, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 10, 2010</results_first_posted>
  <last_update_submitted>July 1, 2011</last_update_submitted>
  <last_update_submitted_qc>July 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Harold Bays MD</name_title>
    <organization>L-MARC Research Center</organization>
  </responsible_party>
  <keyword>Bile acid sequestrant</keyword>
  <keyword>Resin</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>Diabetes mellitus</keyword>
  <keyword>Lipids</keyword>
  <keyword>Glucose</keyword>
  <keyword>Bile Acid Sequestrant Acceptability Scale (BASA)validation study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bile Acids and Salts</mesh_term>
    <mesh_term>Cholestyramine Resin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment started in January 2010 and ended in February 2010. Enrollment officially closed on February 25th, 2010. All patient screening and study visits were conducted at L-MARC Research Center's clinic.</recruitment_details>
      <pre_assignment_details>Enrolled subjects were required to meet all of the inclusion and none of the exclusion criteria prior to being randomized to a group assignment. Subjects were also required to undergo vital sign obtainment, a brief physical exam, and a medical history review to ensure they were generally healthy.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cholestyramine 4 Grams vs 12 Grams vs Tang</title>
          <description>Although 3 different arms are used in this study, there is only one study group. All subjects receive all 3 treatment arms on the same day, just in varying orders. Thus, the participant flow and baseline characteristics are the same for all three arms.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cholestyramine 4 Grams vs 12 Grams vs Tang</title>
          <description>Although 3 different arms are used in this study, there is only one study group. All subjects receive all 3 treatment arms on the same day, just in varying orders. Thus, the participant flow and baseline characteristics are the same for all three arms.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Although 3 different arms are used in this study, there is only one study group. All subjects receive all 3 treatment arms on the same day, just in varying orders. Thus, the age characteristics are the same for all three arms.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Although 3 different arms are used in this study, there is only one study group. All subjects receive all 3 treatment arms on the same day, just in varying orders. Thus, the age characteristics are the same for all three arms.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.2" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Although 3 different arms are used in this study, there is only one study group. All subjects receive all 3 treatment arms on the same day, just in varying orders. Thus, the gender characteristics are the same for all three arms.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Although 3 different arms are used in this study, there is only one study group. All subjects receive all 3 treatment arms on the same day, just in varying orders. Thus, the regions of enrollment are the same for all three arms.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Enrollment Numbers</title>
          <description>Although 3 different arms are used in this study, there is only one study group. All subjects receive all 3 treatment arms on the same day, just in varying orders. Thus, total enrollment number is reflective of all study subjects who participated in the trial.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient Acceptability of Orange-flavored Generic Questran (Cholestyramine) vs. Tang (a Commercial Powdered Orange Drink) Via 2 Versions of a Bile Acid Sequestrant Acceptability (BASA) Scale.</title>
        <description>The Bile Acid Sequestrant Acceptability Scale has 4 scoring categories: taste, texture, appearance and mixability. Participants rank each category separately. The best possible score for each category is 5 and the worst possible score is 1.</description>
        <time_frame>1 Day</time_frame>
        <population>Only 42 total subjects were randomized and analyzed. However, all 42 subjects received all 3 treatment arms, just in varying order of administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Cholestyramine 4 Grams</title>
          </group>
          <group group_id="O2">
            <title>Cholestyramine 12 Grams</title>
          </group>
          <group group_id="O3">
            <title>Tang</title>
          </group>
        </group_list>
        <measure>
          <title>Patient Acceptability of Orange-flavored Generic Questran (Cholestyramine) vs. Tang (a Commercial Powdered Orange Drink) Via 2 Versions of a Bile Acid Sequestrant Acceptability (BASA) Scale.</title>
          <description>The Bile Acid Sequestrant Acceptability Scale has 4 scoring categories: taste, texture, appearance and mixability. Participants rank each category separately. The best possible score for each category is 5 and the worst possible score is 1.</description>
          <population>Only 42 total subjects were randomized and analyzed. However, all 42 subjects received all 3 treatment arms, just in varying order of administration.</population>
          <units>Units on Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Taste Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.1"/>
                    <measurement group_id="O2" value="2.5" spread="0.1"/>
                    <measurement group_id="O3" value="4.2" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Texture Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.2"/>
                    <measurement group_id="O2" value="2.0" spread="0.2"/>
                    <measurement group_id="O3" value="4.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appearance Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.1"/>
                    <measurement group_id="O2" value="2.8" spread="0.1"/>
                    <measurement group_id="O3" value="4.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixability Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.1"/>
                    <measurement group_id="O2" value="2.1" spread="0.2"/>
                    <measurement group_id="O3" value="4.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The BASA scale components were derived from the parameters best shown to differentiate acceptability between different BAS preparations (taste and texture),as well as other parameters useful for differentiating between different BAS preparations(appearance and mixability). The scale was then weighted based upon an “Importance of Acceptability” questionnaire regarding the individual scale components. The developed scale should reasonably allow for future comparisons of differing BAS formulations.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Differences between test products were assessed by repeated measures analysis of variance. If sequence was not found to be statistically significant(p&gt;0.05),then it was removed from the final model.</p_value_desc>
            <method>measures analysis of variance</method>
            <method_desc>Differences between test powders assessed by repeated measures analysis of variance, pairwise comparisons between treatments by Scheffe procedure.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weighted vs. Unweighted BASA Scale</title>
        <description>The total aggregate scores for the complete BASA scale were calculated for Cholestyramine 4g, Cholestyramine 12g, and Tang. The total best possible score was 20 and the total worst possible score was 4. A weighted aggregate BASA scale score was also calculated for the Cholestyramine 4g, Cholestyramine 12g, and Tang. The best possible weighted score was 60 and the worst possible weighted score was 4.</description>
        <time_frame>1 Day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cholestyramine 4 Grams</title>
          </group>
          <group group_id="O2">
            <title>Cholestyramine 12 Grams</title>
          </group>
          <group group_id="O3">
            <title>Tang</title>
          </group>
        </group_list>
        <measure>
          <title>Weighted vs. Unweighted BASA Scale</title>
          <description>The total aggregate scores for the complete BASA scale were calculated for Cholestyramine 4g, Cholestyramine 12g, and Tang. The total best possible score was 20 and the total worst possible score was 4. A weighted aggregate BASA scale score was also calculated for the Cholestyramine 4g, Cholestyramine 12g, and Tang. The best possible weighted score was 60 and the worst possible weighted score was 4.</description>
          <units>Units on Scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total BASA Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="0.4"/>
                    <measurement group_id="O2" value="9.4" spread="0.4"/>
                    <measurement group_id="O3" value="16.7" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weighted BASA Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" spread="1.3"/>
                    <measurement group_id="O2" value="22.6" spread="1.2"/>
                    <measurement group_id="O3" value="41.3" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time the subject signed the informed consent to up to 7 days after the study visit.</time_frame>
      <desc>Adverse events were assessed in clinic during the study visit and through a follow-up phone call 1-7 days after the study visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cholestyramine 4 Grams</title>
        </group>
        <group group_id="E2">
          <title>Cholestyramine 12 Grams</title>
        </group>
        <group group_id="E3">
          <title>Tang</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Belching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Loose Stool</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Gas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Urge to have bowel movement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>(1)It was performed in generally healthy subjects, for whom lipid-altering medication may not be indicated.(2)The subjects’ preference or dislike of the 1st or 2nd powder mixture might have influenced their ratings of the 2nd or 3rd powder.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Harold E. Bays, MD</name_or_title>
      <organization>Louisville Metabolic and Atherosclerosis Research Center (L-MARC)</organization>
      <phone>502-515-5672</phone>
      <email>HBaysMD@aol.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

